FDA Clears the Way for NeuroSense's PrimeC Candidate for ALS

A U.S. Food and Drug Administration Investigational New Drug (IND) application has been approved for NeuroSense Therapeutics’s PrimeC, a potential therapeutic targeting amyotrophic lateral sclerosis (ALS). The drug candidate uses a unique combination-drug formulation to inhibit mechanisms that contribute to the neurodegenerative effects associated with ALS.